Singapore HSA issued Veredus Laboratories with Provisional Authorisation for LIONRUN Diagnostic Kit for Antibody IgM/IgG of Novel Coronavirus COVID-19 for In vitro Diagnostic (IVD) use

Veredus Laboratories Pte Ltd “Veredus” announced today that it has received Provisional Authorisation from Singapore Health Sciences Authority (HSA) for LIONRUN Diagnostic Kit for Antibody IgM/IgG of Novel Coronavirus COVID-19 “LIONRUN Antibody Kit”. Veredus can supply to the healthcare institutions, private hospitals, medical clinics or clinical laboratories licensed under the PHMC Act (Cap. 248) for use on their patients.
LIONRUN Antibody Kit is a colloidal gold IgM/IgG immunochromatography antibody test and is intended for the qualitative and differential detection of IgM and IgG antibodies against the 2019 novel Coronavirus (2019-nCoV) also known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human whole blood, serum or plasma, capable of providing test results in 10 minutes. LIONRUN Antibody Kit is a product manufactured by Shanghai LiangRun Biomedicine Technology Co. Ltd.
Dr Rosemary Tan, CEO of Veredus Laboratories said “We are proud to receive this Provisional Authorisation for LIONRUN Antibody Kit to be used directly on patients in Singapore as an alternative to molecular laboratory testing. This lays a path for clinical testing to be performed outside a central laboratory where local communities can be screened at frontline and triage centers in a time- and cost-effective manner.”